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Purpose: This study was undertaken to review the long-term results of catheter-directed thrombolysis in treatment of
infrainguinal bypass graft occlusion.
Methods: From January 1987 to December 1998, 67 patients with 69 acutely occluded infrainguinal arterial bypass grafts
(48 vein grafts, 21 prosthetic grafts) underwent treatment with catheter-directed thrombolysis with urokinase. Long-
term results were assessed with Kaplan-Meier life-table analysis, and factors predictive of success were determined with
multivariate analysis.
Results: Thrombolysis was aborted in 7 patients (10%) because of major complications or technical failure and was
unsuccessful in restoring graft patency (<90% lysis) in 13 patients (19%). Successful lysis was achieved in 49 patients
(71%). A causative lesion was identified and treated with percutaneous transluminal angioplasty (PTA) or limited
operative revision in 33 patients. Diffuse vein graft intimal hyperplasia or poor runoff was identified in the remaining 9
patients, who were offered no further intervention. Cumulative patency at 60 months was 65% 8% for successfully lysed
vein grafts; however, only 3 of 16 successfully lysed prosthetic grafts were patent at 9 months. Although univariate
analysis identified several factors associated with successful long-term vein graft function, only white race was significant
at multivariate regression analysis.
Conclusions: Coupled with identification and aggressive treatment of underlying causative lesions, catheter-directed
thrombolysis can salvage many thrombosed vein grafts, with expectation of long-term patency similar to that with repeat
bypass grafting. Poor short-term results of thrombolysis of occluded prosthetic grafts support repeat operation with a
completely new bypass graft as a more appropriate option. (J Vasc Surg 2003;37:1009-16.)
Ideal management of occluded infrainguinal arterial
bypass grafts remains controversial. Graft thrombosis with
acute lower extremity ischemia is associated with a high rate
of limb loss and significant patient morbidity and mortality.
Traditional therapy with balloon catheter thrombectomy
and graft revision is associated with consistently poor long-
term graft patency.1,2 Catheter-directed thrombolysis was
introduced as a treatment option for occluded bypass grafts
in the early 1980s and was initially received with consider-
able enthusiasm. The purported advantages of this tech-
nique, including avoidance of mechanical injury to the
endothelium and more complete lysis of clot in the graft
and runoff vessels, made it an ideal therapy for acute graft
occlusion. Indeed, early outcomes were encouraging, with
several studies documenting a greater than 70% initial
success rate.3-9 However, further evaluation revealed poor
long-term graft function, particularly for autogenous vein
grafts, with patency rates averaging only 26% at 3 years.3-6,9
Such discouraging results led some surgeons to abandon
lytic therapy in favor of placing a completely new bypass
graft when faced with a failed infrainguinal graft.5 Because
our results with catheter-directed thrombolysis seemed
better than those in the published literature and supported
a continued role for thrombolysis in treatment of failed
infrainguinal bypass grafts, we undertook this review of our
experience.
METHODS
Patients. Using the computerized database of the
Vascular Surgery registry and the daily logs of the Special
Procedures Division of the Department of Radiology, we
identified all patients undergoing catheter-directed throm-
bolysis to treat acute infrainguinal graft occlusion at our
institution between January 1987 and December 1998.
This interval was chosen because during this period uroki-
nase was the exclusive agent used for catheter-directed
thrombolysis. Sixty-seven consecutive patients with 69 in-
frainguinal bypass graft occlusions underwent catheter-
directed thrombolysis during this period. Selection criteria
for thrombolysis included acute (less than 14 days) symp-
toms of graft occlusion with a viable or threatened limb as
determined by the Society for Vascular Surgery/Interna-
tional Society for Cardiovascular Surgery (SVS/ISCVS)
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committee on reporting guidelines for acute lower extrem-
ity ischemia.10 Patients with irreversible limb ischemia or
significant comorbid conditions were not considered for
lytic therapy. Patients with absolute contraindications to
thrombolysis, including stroke or gastrointestinal hemor-
rhage in the previous 3 months; abdominal, intracranial, or
chest surgery in the previous 60 days; or history of intracra-
nial tumor underwent surgery with graft thrombectomy or
revision, placement of a new graft, amputation, or observa-
tion, as appropriate. Standard demographic data were re-
corded for each patient, as were risk factors identified in the
literature as predictive of initial success and long-term graft
function, including interval from performance of bypass
grafting to graft occlusion (graft age), type of bypass con-
duit, distal target artery, duration of symptoms before
presentation (ischemic interval), and angiographic findings
during therapy.
Angiography and thrombolysis. Diagnostic angiog-
raphy was performed through a retrograde puncture of the
contralateral femoral artery in most patients, to determine
the level of thrombosis, identify any correctable inflow
lesions, and evaluate collateral circulation. A guide wire was
then passed through the occluded graft; if this was unsuc-
cessful, the procedure was usually aborted. Occasionally a
short course of high-dose urokinase was required to suc-
cessfully pass the guide wire. A multi-side hole catheter was
threaded over the guide wire and placed 1 to 2 cm from the
distal end of the clot. The distal tip of this catheter was then
occluded with a guide wire, and urokinase was adminis-
tered.
The urokinase protocol evolved over the course of the
study, but generally consisted of a combination of high-
dose pulse-spray and continuous overnight infusions. In
the pulse-spray technique 250,000 to 500,000 IU of uroki-
nase was infused over 1 to 2 hours, with angiography
performed at 10-minute to 60-minute intervals. During
continuous infusion, doses of 1000 to 2000 IU/min were
given, on average over 18 hours (range, 1-100 hours). A
combination of these techniques was used in 34 patients
(49%), and 28 patients (41%) received continuous infusion
alone. The remaining 7 patients (10%) received pulse-spray
without continuous infusion. The total dose of urokinase
averaged 2,300,000 IU (range, 250,000-14,580,000 IU)
per patient.
Thrombolysis was continued until one of the following
end points was met: complete clot lysis (90% by volume)
with restoration of antegrade flow, persistent thrombus
with failure of progressive lysis on serial arteriograms, or
complications that required premature termination of the
procedure. Causative lesions identified during lytic therapy
were treated with PTA or limited surgical revision consist-
ing of patch angioplasty, interposition grafting of a stenotic
segment, or a distal jump graft from a patent section of
bypass graft to a more distal target artery.
Patients were monitored in the intensive care unit or a
step-down unit while undergoing lytic therapy. Continu-
ous intravenous infusion of unfractionated heparin sodium
was administered to prevent peri-catheter thrombosis,
maintaining partial thromboplastin time at two to two and
one-half times normal. Close observation of the catheter
insertion site was maintained to detect early signs of hem-
orrhagic complications. Serial determinations of hemoglo-
bin, fibrinogen, and partial thromboplastin time were ob-
tained. Urokinase infusion was discontinued if there was a
major bleeding episode, and the dosage was reduced if
fibrinogen level fell below 100 mg/dL. Prophylactic anti-
biotic agents (usually a cephalosporin) were administered
while arterial catheters were in place.
Complete lower extremity arteriography was per-
formed at the termination of thrombolytic therapy. This
study was used to quantify extent of clot lysis, determine
status of the distal runoff bed, and identify any potential
causative lesions. Status of distal runoff was rated with the
SVS/ISCVS grading system.10 Successful lysis was defined
as clot dissolution 90% or greater. On the basis of this
criterion, patients were stratified into two groups: success-
ful lysis and unsuccessful lysis. Successfully lysed grafts were
managed according to findings on the completion angio-
gram. Correctable causative lesions were treated either
immediately with PTA or within a few days with operative
revision (Fig 1). After correction of causative lesions, pa-
tients were discharged with prescribed aspirin or warfarin
sodium therapy and followed-up in the outpatient clinic at
regular intervals. Patients without causative lesions were
given long-term anticoagulation therapy (usually both as-
pirin and warfarin sodium) after undergoing testing to rule
out thrombophilia. Patients with diffuse graft hyperplasia
(uncorrectable causative lesion) were evaluated for repeat
bypass grafting.
Graft patency was monitored in the outpatient clinic
with segmental pressure testing or duplex scanning. Long-
term graft patency was defined from the date of thrombol-
ysis, not from the date of the initial graft construction.
Although by strict definition this value represents second-
ary graft patency, for the purpose of this analysis the qual-
ifier “secondary” was dropped to avoid possible confusion.
The reporting interval for patients who were lost to fol-
low-up or died with open grafts was ended at the time of
the patient’s last examination. Asymptomatic graft failure
after successful thrombolysis was reported as having failed
halfway between the last visit when the graft was open and
the time of documented closure, per SVS/ISCVS guide-
lines.10
Statistical analysis. Differences between demo-
graphic data, comorbid conditions, and graft-related fac-
tors were determined with the 2 test for significance, and
the Fisher exact test when appropriate. Survival, graft pa-
tency, and limb salvage rates were determined with the
Kaplan-Meier method. Differences in long-term outcome
between prosthetic and vein grafts were not subjected to
statistical comparison, because of the low number of pros-
thetic grafts available for analysis. Univariate analysis with
the Mantel-Cox log-rank test was used to identify factors
associated with long-term patency. These factors were then
subjected to multivariate regression analysis with a propor-
tional hazards model. P  .05 was considered significant.
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RESULTS
The study group consisted of 67 patients with 69 grafts
(48 vein grafts, 21 prosthetic grafts). Forty-one patients
(61%) were men and 26 patients (39%) were women;
average age was 68 years (range, 22-90 years). The distal
target was the popliteal artery in 29 grafts (42%), a tibial
artery in 35 grafts (51%), and a pedal vessel in 5 grafts (7%).
Bypass grafts were in place on average for 20.7 months
(range, 1 month to 11.5 years) at the time of occlusion. The
average ischemic interval was 57 hours (range, 6 hours to
14 days). Graft occlusion was manifested by ischemic rest
pain in 50 patients (72%) and extreme short-distance clau-
dication in 19 patients (28%). Fifty-three patients (77%)
had a threatened limb (category IIa or IIb on the SVS/
ISCVS acute limb ischemia scale); the remaining 16 limbs
(23%) were considered viable (category I).10 Thirty-one
patients (55%) were white, and 30 patients (45%) were
African American. Comorbid conditions and their associa-
tion with successful thrombolysis are summarized in Table
I.
The outcome in all patients undergoing catheter-di-
rected thrombolysis is summarized in Fig 1. Thrombolysis
was aborted in 7 of 69 patients (10%), because of contrast
extravasation (2 patients), catheter insertion site bleeding
(3 patients), and cardiac complications (2 patients). Five of
these patients had vein grafts, and 2 had prosthetic grafts.
Two of these patients underwent subsequent operative
thrombectomy. A repeat bypass procedure was necessary in
1 of these patients, and the other required amputation 2
months later. Two patients were given anticoagulation
therapy after thrombolysis was aborted. One of these pa-
tients underwent a secondary bypass procedure 4 months
later; the other maintained limb viability without further
intervention. The remaining 3 patients required amputa-
tion within 10 weeks of the procedure.
Thrombolysis was unsuccessful in restoring graft pa-
tency in 13 of 69 patients (19%), and therapy was termi-
nated after follow-up arteriograms showed no progression
of lysis with continued infusion. These patients had 10 vein
grafts and 3 prosthetic grafts. Two patients underwent
subsequent repeat bypass grafting, with limb salvage. One
patient received no further treatment and died of conges-
tive heart failure 1 month later. The remaining 10 patients
required amputation within 10 weeks of unsuccessful lytic
therapy.
Successful lysis was achieved in 49 of 69 patients (71%)
with 33 vein grafts and 16 prosthetic grafts. A causative
lesion was identified and corrected in 33 of these 49 grafts
(67%). Treatment included PTA of focal lesions in 18
patients, operative revision in 9 patients with more diffuse
Fig 1. Initial results of catheter-directed thrombolysis in 67 patients with 69 grafts. VG, Vein grafts; PG, prosthetic
grafts; ID, identified; PTA, percutaneous transluminal angioplasty. *Long-term patency and limb salvage data based on
these 49 patients.
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lesions, and a combination of PTA and operative interven-
tion in the remaining 6 patients. Operations consisted of 7
vein patch angioplasties, 5 interposition grafts, and 3 distal
jump grafts. Five-year limb salvage in this group for vein
grafts was 21 of 22 (95%) and for prosthetic grafts was 6 of
11 (55%).
In 7 of 49 patients (15%) in whom thrombolysis was
successful, no causative lesion could be identified. These
patients were given long-term anticoagulation therapy after
undergoing testing to rule out thrombophilia. No named
hypercoaguable state could be identified in any patient.
There were 3 vein grafts and 4 prosthetic grafts in this
subset of patients. Five-year limb salvage in this group was
2 of 3 (67%) for vein grafts and 3 of 4 (75%) for prosthetic
grafts.
The remaining 9 of 49 patients (18%) had diffuse vein
graft intimal hyperplasia or poor distal runoff. In these
patients catheter-directed thrombolysis was considered
technically successful but clinically unsuccessful. Seven of
these patients required amputation during follow-up. The
remaining 2 patients were lost to follow-up.
No patient died as a direct result of catheter-directed
thrombolysis, though 3 serious cardiac complications were
related to the procedure. In 1 patient with critical aortic
stenosis, congestive heart failure developed shortly after
termination of thrombolysis, and the patient died after a
1-month course of intensive care. Two other patients had
acute myocardial infarctions during the procedure. Com-
plications of thrombolysis are summarized in Table II.
Long-term graft patency for the 49 successfully lysed
infrainguinal grafts is shown in Fig 2. Vein grafts had a
cumulative patency of 65% 8 at 5 years, whereas only 3 of
16 successfully lysed prosthetic grafts were open at 9
months. Aborted and unsuccessful attempts at thromboly-
sis were not included in this analysis. Limb salvage in
patients undergoing successful thrombolysis is shown in
Fig 3. Five-year limb salvage rate for vein grafts was 76%
8. The standard error for limb salvage was greater than 10%
after 6 months for prosthetic grafts, and approached 20% at
46 months when the cumulative rate of limb salvage was
41%. Five-year survival in patients with successfully lysed
grafts is shown in Fig 4. Cumulative survival was similar for
patients with vein grafts and prosthetic grafts (77% and
75%, respectively); however, again the standard error for
prosthetic grafts was greater than 10% at 8 months.
Demographic data, comorbid conditions, and graft
characteristics identified in the literature as predictors of
long-term graft function were evaluated with univariate
and multivariate analysis. The results are summarized in
Tables III and IV. Although univariate analysis enabled
identification of several factors associated with favorable
long-term graft function, only white race proved significant
at multivariate analysis. In an effort to identify factors that
contributed to poor outcome observed in African American
patients, the significant predictors of graft function were
further stratified by race (Table V). Post-lysis runoff scores
were more favorable in white patients than in African
American patients, although this difference was not statis-
tically significant.
DISCUSSION
Management of infrainguinal bypass graft occlusion
remains problematic. Balloon catheter thrombectomy with
operative revision of causative lesions has historically been
associated with dismal outcome.1,2 As a result, many sur-
geons have abandoned this approach in favor of a com-
pletely new bypass graft. However, when an adequate
length of autogenous vein is available, such secondary
bypass grafts are associated with only modest 5-year pa-
tency rates.13 When patients have no remaining usable vein,
surgeons are forced to use prosthetic grafts or composite
prosthetic-vein grafts, which have even worse long-term
patency rates.14
Table I. Influence of patient demographics and
comorbid conditions on success of thrombolysis
Factor
(no. of patients) Successful CDT Unsuccessful CDT P
Gender .824
Male (43) 30 13
Female (26) 18 8
Age at presentation (y) .076
60 (51) 32 19
60 (18) 16 2
Race .021
White (37) 30 7
African American (30) 16 14
Graft status .781
Primary bypass (46) 33 13
Repeat bypass (23) 15 8
Graft age (y) .824
1 (43) 30 13
1 (26) 18 8
Conduit .612
Vein (48) 32 16
Prosthetic (21) 16 5
Ischemic interval (h) .026
48 (17) 16 1
48 (52) 32 20
Diabetes .776
Present (33) 24 9
Absent (36) 24 12
Renal failure .119
Present (9) 4 5
Absent (60) 44 16
Tobacco use .181
Present (50) 32 18
Absent (19) 16 3
Coronary artery disease .623
Present (38) 25 13
Absent (31) 23 8
Hypertension 1.000
Present (59) 41 18
Absent (10) 7 3
Distal anastomosis .628
Popliteal (29) 20 9
Tibial/pedal (40) 28 12
Ischemia severity* .120
Viable limb (16) 14 2
Threatened limb (53) 34 19
CDT, Catheter-directed thrombolysis.
*Ischemia severity according to SVS/ISCVS criteria.10
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The advent of catheter-directed thrombolysis added a
new therapeutic option to management of occluded in-
frainguinal bypass grafts. This approach has numerous the-
oretic advantages, including avoidance of mechanical
trauma to the endothelium associated with passage of a
balloon thrombectomy catheter, more complete removal of
thrombus from within the occluded graft, and improved
outflow from clearing clot from surgically inaccessible run-
off vessels. After successful lysis, underlying causative le-
sions can be identified and corrected on a semi-elective
basis, averting emergency surgery in unprepared patients.
In some cases, culprit lesions can be treated with PTA,
averting surgical intervention altogether. The major disad-
vantages of catheter-directed lysis include a baseline failure
rate as high as 30% and hemorrhagic complications. This
approach is further limited by the additional hours of
ischemia that the threatened limb must tolerate during clot
lysis.
Our institutional protocol for catheter-directed throm-
bolysis evolved over the 11-year study period. No attempt
was made to differentiate between low-dose and high-dose
therapy with regard to lytic success or rate of complication.
The approach used in most patients included an initial
pulse-spray of urokinase followed by continuous infusion of
1000 to 2000 IU/min, with the progression of clot lysis
monitored with serial arteriography. The initial phase of the
Thrombolysis or Peripheral Arterial Surgery (TOPAS)
study evaluated the efficacy and safety of urokinase doses
ranging from 2000 to 6000 IU/min and found no signif-
icant difference in rate of successful lysis or bleeding com-
Fig 2. Cumulative patency rates for successfully lysed bypass
grafts as determined with the Kaplan-Meier method. Upper values
represent number of vein grafts at risk at each given time. Lower
values represent prosthetic grafts at risk at each given time.
Fig 3. Cumulative limb salvage for successfully lysed bypass grafts
as determined with the Kaplan-Meier method. Upper values rep-
resent number of vein grafts at risk at each given time. Lower values
represent prosthetic grafts at risk at each given time.
Table II. Complications of catheter-directed thrombolysis
Complication
Patients
Therapy
Limb salvage
n % n %
Distal embolism 13 19 Resolved with UK 10 of 13 77
Cardiac 3 4 2 of 3 67
MI 2 Stopped UK
CHF 1 Death in ICU
Technical 9 13 3 of 9 33
Extravasation 4 Stopped UK
Pericatheter thrombosis 3 Stopped UK
Access site pseudoaneurysm 2 Operative repair
Bleeding 11 16 6 of 11 54
Access site hematoma 10 Transfusion (n  4 pts)
Gastrointestinal bleed 1 Transfusion
UK, Urokinase; MI, myocardial infarction; CHF, congestive heart failure; ICU, intensive care unit.
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plications.11 In our series, continuous infusion of urokinase
never exceeded 2000 IU/min, and the associated major
bleeding rate of 9% is similar to that in previous trials. More
important, no episodes of intracranial hemorrhage oc-
curred at this infusion rate.
Initial reports of catheter-directed thrombolysis to treat
occluded infrainguinal bypass grafts were encouraging,
with early success rates of 75% to 84%.15,16 However, in
follow-up, graft reocclusion was common with patency
rates of  30% at 3 years, leading several authors to ques-
tion the efficacy of this technique.3,4,9 Several small series
have compared thrombolysis with operative intervention in
the treatment of bypass graft occlusion, but their results are
difficult to interpret because grafts were not stratified by
conduit type or distal target artery.17-20 Two large-scale,
randomized, multicenter trials of thrombolysis versus sur-
gery to treat lower extremity ischemia have also been per-
formed.8,11 However, data analyses in these studies did not
address the success rate of catheter-directed thrombolysis
for treating occluded infrainguinal grafts. The Surgery vs
Thrombolysis for Ischemic Lower Extremity (STILE) trial
grouped native artery thromboses and occluded bypass
grafts together when determining outcomes, whereas the
TOPAS study did not differentiate between suprainguinal
and infrainguinal grafts when calculating graft patency
rates.8,11 Several more recent series that focused only on
infrainguinal bypass grafts have documented poor long-
term graft function after catheter-directed thrombolysis,
with 3-year to 5-year patency rates of only 19% to 28%.3-5
In addition to these overall dismal results, most authors
have reported that vein grafts fare even worse than pros-
thetic grafts after successful thrombolytic therapy.3-4,8-9
This observation has fueled the belief that vein graft throm-
bosis causes irreversible endothelial damage, rendering ve-
nous conduits more vulnerable to recurrent occlusion.
The results of the current study stand in marked con-
trast to these earlier series. Long-term patency of success-
fully lysed vein grafts was not only superior to that of
prosthetic grafts, but was much better than in any previous
reports. This discrepancy in outcome is hard to explain, but
it may be related to differences in duration of graft occlu-
Fig 4. Cumulative survival for successfully lysed bypass grafts as
determined with the Kaplan-Meier method. Upper values repre-
sent number of vein grafts at risk at each given time. Lower values
represent prosthetic grafts at risk at each given time point.
Table III. Univariate analysis of factors affecting patency
in successfully lysed vein grafts
Factor 60-month patency (%) P
Ischemic interval (h) .027
48 70
48 40
Correctable causative lesion .002
Yes 81
No 30
Race .0002
White 83
African American 27
Smoking history .758
Present 64
Absent 50
Distal anastomosis .020
Popliteal 92
Tibial/pedal 58
Graft age (y) .214
1 57
1 86
Gender .519
Male 73
Female 53
Diabetes .868
Present 61
Absent 57
Hypertension .760
Present 64
Absent 67
Table IV. Multivariate analysis of significant factors
identified with univariate analysis
Factor P
Graft age (1 y) .431
Ischemic interval (48 h) .283
Distal anastomosis (popliteal) .091
Race (white) .008
Correctable causative lesion .278
Table V. Predictors of poor graft function: Effect of race
Risk factor White (%) African American (%) P
Graft age (12 mo) 70 86 .30
Ischemic interval (48 h) 74 86 .48
Tibial/pedal anastomosis 74 81 .73
No correctable causative
lesion identified
48 67 .32
Runoff score 4.0 5.4 .24
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sion before presentation (ischemic interval) between these
series. Hye et al,3 Nackman et al,4 and Berkowitz and Kee5
reported an average ischemic interval of 6 to 8 days, and
performed thrombolysis in patients with occlusions as old
as 90 days. In contrast, our average ischemic interval was
only 2.3 days, and patients with symptoms for more than
14 days were not offered lytic therapy. The importance of
the duration of the ischemic interval on the long-term
success of thrombolysis has been previously recognized.4,12
In the series of Nackman et al, as well as the current report,
grafts occluded for less than 48 hours clearly fared better
than those occluded longer. Endothelial damage caused by
the presence of thrombus appears to be reversible in the
acute setting. Longer ischemic intervals are associated with
more extensive endothelial injury and increased thrombo-
genicity. Furthermore, there may be a thin layer of pro-
thrombotic material that persists after successful graft lysis
and serves as a catalyst for future thrombotic events. A
functioning endothelium would protect against this film in
lysed vein grafts, but lysed prosthetic grafts would not have
this same protection. As a result, lysed prosthetic grafts may
be at higher risk for thrombosis than an entirely new
prosthetic graft. The short-term patency for successfully
lysed prosthetic grafts in the current series was so poor that
currently we rarely offer lytic therapy to patients with these
grafts.
Duration from initial bypass to graft occlusion also
affects long-term patency.3-5 Hye et al3 and Nackman et al4
demonstrated that grafts that had been in place longer than
1 year fared much better after thrombolysis than those that
had not. In the series of Berkowitz and Kee,5 the only
variable associated with reasonable long-term patency was
graft age greater than 10 months.5 These observations are
consistent with our experience. Vein grafts that thrombose
after 1 month but within the first year of initial bypass are
often inferior conduits, eg, with sclerotic or small-diameter
veins. After successful lysis, intrinsic defects persist, making
long-term patency less likely without extensive revision or
replacement. Grafts with late failure (after 1 year) have had
a chance to mature, developing nutrient blood flow from
both adventitial capillary ingrowth and luminal diffusion.
Such grafts may be more resistant to ischemia than younger
grafts, whose nutrient supply depends solely on intralumi-
nal blood flow.5
In our series, grafts in patients in whom a causative
lesion was identified and repaired with PTA or limited
surgical revision, and in patients with popliteal anastomoses
had better long-term patency than grafts in patients with no
identifiable lesion or more distal anastomoses. These find-
ings have been reported by others.7,19 Although no named
thrombophilic condition could be identified in any of the 7
patients without a causative lesion, it seems likely that some
form of hypercoaguability contributed to graft occlusion.
The presence of some degree of thrombophilia places these
patients at continued risk for graft occlusion even with
aggressive antithrombotic regimens. The improved out-
come in patients with distal target arteries at the popliteal
level is consistent with the natural history of infrainguinal
vein grafts.
The only significant predictor of poor long-term vein
graft patency identified with multivariate analysis in this
series was African American race. This factor was also
identified by Ouriel and Veith21 as a predictor of poor
outcome, regardless of method of infrainguinal bypass graft
salvage. Several observations may explain this finding. In
our series, African American patients were more likely to
have graft occlusion within a year of initial bypass grafting.
They also had longer ischemic intervals and fewer correct-
able causative lesions than did white patients. In addition,
African American patients were more likely to have a tibial
or pedal artery as the distal target for the bypass. However,
none of these factors reached statistical significance with
univariate analysis and therefore cannot completely explain
the poor outcome in African American patients. The rec-
ognized higher incidence of more severe distal disease in
black patients may adversely affect long-term patency
rates.22 Distal runoff scores were calculated with the SVS/
ISCVS grading system at the end of each course of catheter-
directed thrombolysis. The average runoff score for African
American patients with successfully lysed vein grafts was
5.4, compared with 4.0 for white patients. Although runoff
scores are not a practical pre-intervention predictor of
long-term success, the reduced outflow seen in black pa-
tients confirms their propensity for small artery disease and
may help explain the poorer long-term patency in this
group.
Contrary to previous reports in the literature, the re-
sults of our study demonstrate a continued role for cathe-
ter-directed thrombolysis in treatment of acutely occluded
infrainguinal bypass grafts. Coupled with an aggressive
search for and treatment of underlying causative lesions,
thrombolytic therapy can salvage many occluded vein
grafts, with an expectation of reasonable long-term pa-
tency. Although most prosthetic grafts can be successfully
opened with thrombolysis, short-term patency is poor,
suggesting that repeat surgery to place a new graft may be a
more appropriate option. Racial differences in outcome
remain unexplained and should be addressed in future
studies.
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